4.5 Article

Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder

期刊

EUROPEAN NEUROPSYCHOPHARMACOLOGY
卷 23, 期 8, 页码 895-901

出版社

ELSEVIER
DOI: 10.1016/j.euroneuro.2012.09.002

关键词

Depression; Treatment resistance; Treatment response; Physical co-morbidity

资金

  1. Lundbeck

向作者/读者索取更多资源

Co-morbid physical illness has been suggested to play an important role among the factors contributing to treatment resistance in patients with major depressive disorder. In the current study we compared the rate of physical co-morbidity, defined by ICD-10, among a large multicenter sample of 702 patients with major depressive disorder. A total of 356 of the participants were defined as treatment resistant depression (TRD) patients-having failed two or more adequate antidepressant trials. No significant difference was found between TRD and non-TRD participants in the prevalence of any ICD-10 category. This finding suggests that although physical conditions such as diabetes, thyroid dysfunction, hypertension, ischemic heart disease, and peptic diseases are often accompanied by co-morbid MOD, they do not necessarily have an impact on the course of MOD or the likelihood to respond to treatment. Marginally higher rates of co-morbid breast cancer, migraine and glaucoma were found among TRD participants. Possible explanations for these findings and their possible relation to TRD are discussed. (C) 2012 Elsevier B.V. and ECNP. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Psychology, Clinical

Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank

Chiara Fabbri, Julian Mutz, Cathryn M. Lewis, Alessandro Serretti

Summary: This study was the first to comprehensively evaluate the predictors of wellbeing in relation to the history of MDD. The identified variables are important to identify individuals at risk and promote wellbeing.

PSYCHOLOGICAL MEDICINE (2023)

Article Psychiatry

Cariprazine for treating psychosis: an updated meta-analysis

Marcelo B. Generoso, Ivan Taiar, Quirino Cordeiro, Pedro Shiozawa, Siegfried Kasper

Summary: Early treatment of psychotic illness is important for better outcomes, and cariprazine, a promising antipsychotic drug, may be beneficial in treating psychosis regardless of the diagnosis of schizophrenia or bipolar disorder.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Editorial Material Neurosciences

Investigation of Psychoactive Medications: Challenges and a Practical and Scalable New Path

Dekel Taliaz, Alessandro Serretti

Summary: The validity of clinical trials in psychiatry has been under discussion in the past two decades. The commonly used method of randomized controlled trials (RCTs) faces challenges when applied in the psychiatric field due to strict participant criteria and inconsistency in endpoint parameters. This has led to problematic clinical practice in psychiatry.

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2023)

Article Psychiatry

Factors associated with sick leave duration in patients suffering from major depressive disorder initiating antidepressant treatment: a real-world evidence study in Germany and Spain

Miquel Roca, Annalisa Bonelli, Agnese Cattaneo, Alessandro Comandini, Giorgio Di Dato, Franca Heiman, Valeria Pegoraro, Siegfried Kasper, Hans-Peter Volz, Diego Palao

Summary: This study explores the impact of pharmacological approaches in treating MDD patients and identifies factors associated with longer sick leave duration. Combination/switch/add-on treatments are associated with a higher risk of longer sick leave periods, while timely and careful selection of antidepressant treatment approach may help reduce sick leave.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Review Psychiatry

Subthreshold depression - concept, operationalisation and epidemiological data. A scoping review

Hans-Peter Volz, Johanna Stirnweiss, Siegfried Kasper, Hans-Juergen Moeller, Erich Seifritz

Summary: This paper reviews the research on subthreshold depression (SD) based on a scoping review. The results show that the operationalisation criteria used are highly heterogeneous, leading to inconsistent epidemiological data. The impact of SD on quality of life and related parameters is similar to that of major depression, and therapeutic approaches can be helpful in both preventing and treating SD.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2023)

Article Pharmacology & Pharmacy

Patterns of antipsychotic prescription and accelerometer-based physical activity levels in people with schizophrenia spectrum disorders: a multicenter, prospective study

Vincenzo Oliva, Giuseppe Fanelli, Manuel Zamparini, Cristina Zarbo, Matteo Rocchetti, Letizia Casiraghi, Fabrizio Starace, Alessandra Martinelli, Alessandro Serretti, Giovanni de Girolamo, DiAPASon Consortium

Summary: Antipsychotic polypharmacy (APP) is commonly used in patients with schizophrenia spectrum disorders (SSDs) despite recommendations against it. This study found high rates of APP and lower levels of physical activity in both residential and outpatient patients. However, patients on APP showed trends of reduced sedentariness and higher levels of light physical activity compared to those on monopharmacy.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Article Psychiatry

Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting

Fabio Panariello, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Alessandro Serretti, Chiara Fabbri

Summary: This study aimed to identify factors associated with side effects of psychotropic drugs in a real-world setting enriched with treatment-resistant depression (TRD) patients. Results showed that the severity of depressive symptoms was associated with total, psychic, and neurological side effects, while autonomic side effects were higher in patients with somatic comorbidities and lower in patients receiving trazodone. Multivariate analyses revealed that depressive symptom severity was associated with psychic and total side effects, generalized anxiety disorder (GAD) with neurological side effects, and somatic comorbidities remained associated with autonomic side effects. Trazodone was associated with lower side effects and with augmentation treatments. Augmentation therapies showed opposite effects depending on response status, i.e. increased or decreased the risk of side effects in responders and non-responders/resistant patients, respectively.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2023)

Article Pharmacology & Pharmacy

Unhealthy lifestyle impacts on biological systems involved in stress response: hypothalamic-pituitary-adrenal axis, inflammation and autonomous nervous system

Laura Mandelli, Yuri Milaneschi, Sarah Hiles, Alessandro Serretti, Brenda W. Penninx

Summary: An unhealthy lifestyle plays a crucial role in the development and progression of chronic disorders, and it may also affect biological systems involved in stress response. Using data from the Netherlands Study of Depression and Anxiety, researchers calculated a global index of unhealthy lifestyle based on five self-reported habits. They found that the index was associated with hyperactivity of the hypothalamus-pituitary-adrenal axis and increased inflammation, indicating that unhealthy habits increase biological stress. The use of drugs also impacted the autonomic nervous system activity.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Editorial Material Pharmacology & Pharmacy

Fine-tuning of psychopharmacological treatments

Alessandro Serretti

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Editorial Material Pharmacology & Pharmacy

The challenge of managing difficult to treat psychiatric conditions

Alessandro Serretti

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2023)

Article Clinical Neurology

Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns

Vincenzo Oliva, Giuseppe Fanelli, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Chiara Fabbri, Alessandro Serretti

Summary: This study found that different clinical subtypes of major depressive disorder (MDD), particularly melancholic features and typical neurovegetative symptoms, may be associated with distinct underlying genetics. These findings contribute to a better understanding of the genetic heterogeneity of MDD.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Review Genetics & Heredity

Genetics of nonpharmacological treatments of depression

Raffaella Zanardi, Matteo Carminati, Francesco Attanasio, Chiara Fabbri, Alessandro Serretti

Summary: Nonpharmacological treatments for depression show effectiveness and tolerability in certain patients with diverse response. Genetic variables associated with treatment efficacy need to be examined to assist treatment selection. Most studies using candidate gene approach yielded poorly replicated findings due to small sample sizes, while a few methylome-wide and genome-wide association studies (GWASs) provided interesting results with the use of polygenic risk scores in small samples of electroconvulsive therapy (ECT) and cognitive-behavioral therapy. Further GWAS with larger sample sizes, such as the gen-ECT-ic consortium, can enhance our understanding of the genetic factors underlying treatment response in nonpharmacological therapies for depression.

PSYCHIATRIC GENETICS (2023)

Article Psychiatry

Hospital inpatient suicides: A retrospective comparison between psychiatric and non-psychiatric inpatients in Milan healthcare facilities

Daniele Rucco, Guendalina Gentile, Stefano Tambuzzi, Beatrice Fanton, Raffaella Calati, Riccardo Zoja

Summary: This retrospective study investigated the characteristics of hospital inpatient suicides in Milan, Italy over a twenty-eight-year period from 1993 to 2020. The study compared the features of suicides in patients with psychiatric diagnoses and those without. Data were collected from historical archives, annual registers, and autopsy reports. The results showed that the majority of inpatient suicides were men of Italian nationality, admitted to non-psychiatric wards, with a single illness, treated with psychotropic medications, who used violent suicide methods and died of organic injuries outside the buildings. Comparing psychiatric and non-psychiatric inpatients, suicide cases with a non-psychiatric diagnosis were predominantly men, hospitalized in non-psychiatric wards, assuming non-psychotropic drugs, and died in outside hospital spaces.

SUICIDE AND LIFE-THREATENING BEHAVIOR (2023)

Review Neurosciences

Anhedonia and Depressive Disorders

Alessandro Serretti

Summary: Anhedonia is a core symptom of depression and other psychiatric disorders, referring to a lack of pleasure or reward. It is not only a psychological distress but also encompasses a range of reward processing deficits. Anhedonia is a relevant risk factor for suicidal behaviors and may operate independently of the severity of depressive episodes. It has also been associated with inflammation, which can have a reciprocal detrimental effect on depression. The neurophysiological bases of anhedonia mainly involve changes in striatal and prefrontal areas, with dopamine playing a key role as the neurotransmitter involved. Anhedonia is believed to have a significant genetic component and polygenic risk scores may be a tool for predicting an individual's risk for developing anhedonia. Traditional antidepressants have shown limited benefit in treating anhedonia, also considering their potential to worsen anhedonia in some individuals. Other treatments such as agomelatine, vortioxetine, ketamine, and transcranial magnetic stimulation may be more effective. Psychotherapy, particularly cognitive-behavioral therapy and behavioral activation, is widely supported as beneficial for anhedonia. In conclusion, evidence suggests that anhedonia is partially independent from depression and requires careful evaluation and targeted treatment.

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2023)

Article Psychiatry

Age as a moderating factor of treatment resistance in depression

Alexander Kautzky, Lucie Bartova, Gernot Fugger, Markus Dold, Daniel Souery, Stuart Montgomery, Joseph Zohar, Julien Mendlewicz, Chiara Fabbri, Alessandro Serretti, Dan Rujescu, Siegfried Kasper

Summary: This study investigates the differences in presentation and treatment outcomes of treatment-resistant depression (TRD) among different age groups. It finds that age has an impact on depressive symptoms and treatment outcomes. In TRD patients, symptom load and hospitalization time increase with age, while treatment responders do not show this trend. Older patients are more likely to have symptoms such as inner tension, reduced appetite, concentration difficulties, and lassitude.

EUROPEAN PSYCHIATRY (2023)

Article Clinical Neurology

A posterior-alpha ageing network is differentially associated with antidepressant effects of venlafaxine and rTMS

Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns

Summary: This study used a polygenic score (PGS) and electroencephalography (EEG) data analysis to identify potential predictors for treatment outcomes in major depressive disorder (MDD). The results suggest the existence of a stable EEG network related to antidepressant-response that has potential as a predictor for MDD treatment, particularly in the case of venlafaxine.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2024)